IFN-α also has immunomodulatory properties and the tumor necrosis factor-related apoptosis inducing ligand (TRAIL) or Fas/Fas-L pathway partially contributes to the anti-tumor effects of IFN-α/5-FU combination therapy [14,15]. The gene discussed is IFNA1; the disease is neoplasm.